Elevre Medical

An image of Miriam Savage from Elevre Medical
Logo of Elevre Medical

Miriam Savage, Elevre Medical

Treating COPD with wearable breathlessness therapy

What problem are you solving and what is innovative about your approach?

Hundreds of millions of people live with debilitating breathlessness worldwide, a symptom of many disease states. The Cleveland Clinic estimates that one in four of all patients that seek ambulatory care has breathlessness.  

In Chronic Obstructive Pulmonary Disease (COPD), the core symptom of breathlessness is widely acknowledged to be poorly managed. Over half of the 250 million people living with COPD worldwide experience disabling levels of breathlessness. This huge clinical problem devastates patient quality of life and burdens healthcare systems as associated costs continue to rise. 

To bring innovation to the neglected space of breathlessness management in COPD, Elevre Medical has created ResWave – a first-of-its-kind wearable therapy for breathlessness. ResWave delivers localised neuromuscular stimulation to the chest wall to provide relief when patients need it most – during physical activity. It can be worn discreetly under clothing and delivers non-invasive therapy with no disruption to the patient. It is the only device to provide this offering and has the potential to help millions of people worldwide.

How is this idea commercially attractive?

Annual healthcare spend in COPD is estimated at a staggering €65 billion in the US and EU, with current treatment focusing on the management of symptoms and reducing risk of exacerbations. As the cardinal symptom, breathlessness contributes significantly to COPD healthcare spend. More severe breathlessness can double COPD healthcare costs. 

In stable COPD with optimised treatment plans, 43% of people still experience persistent and disabling breathlessness that has a devastating impact on their lives. Current breathlessness treatment options are lacking due to impracticality for use or unwanted side effects. This has left a substantial gap in the market for effective, practical, and safe breathlessness therapies. 

The total addressable market for ResWave in the US and EU is estimated at €10.7 billion, and the COPD devices market is forecasted to grow at a CAGR of 4.3% during 2020-2027. Elevre Medical has mapped ResWave’s route to market, with clearly defined regulatory and reimbursement pathways. With its patent-pending technology and scalable business model, ResWave will be the first device on the market that can offer unobtrusive breathlessness relief to patients, making it ideally placed to seize this significant opportunity. 

What do you hope to achieve by participating in Big Ideas?

Elevre Medical are excited to be participating in Big Ideas as the team works towards spin-out from NUIG and ResWave’s first on human clinical evaluation in Q1 2022. We look forward to the opportunity to expand our network, engage with new potential partners and build the company profile as we move to this next phase.